Adir Et Compagnie

Les Laboratoires Servier

Les Laboratories Servier

Bertrand Goument

Jean-Louis Peglion

Mark Millan

Aimee Dessinges

Adrian Newman-Tancredi

Alain Gobert

Valerie Audinot

Anne Dekeyne

Joel Vian

Fran&ccedil;oise Lejeune

Jean-Charles Schwartz

Jean-Christophe P Harmange

Jean-Paul Vilaine

Nicole Villeneuve

Pierre Sokoloff

Jean-Michel Rivet

Clotilde Mannoury La Cour

Didier Cussac

Christophe Poitevin

Catherine Thollon

Mauricette Brocco

Aim&eacute;e Dessinges

Christine Courchay

Pascal Caignard

Stéfano Chimenti

Aimée Dessinges

Marc Konnert

Françoise Gellibert

Val Erie Audinot

Francoise Gellibert

A compound of formula (I): wherein the substituents are as defined in the description. Medicinal products containing the same which are useful in treating or preventing pathologies which are the result of activation of the RhoA/ROCK pathway and phosphorylation of the myosin light chain.

Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them

Compounds of formula (I): wherein: Medicinal products containing the same which are useful in treating various pathologies.

1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them

A compound selected from those of formula (I): wherein: Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NKantagonist.

Piperazine compounds

Cyclobutaindolecarboxamide compounds

Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds

A compound of formula (I): ##STR1## wherein: R.sub.1, R.sub.2 and R.sub.3, which may be the same or different, represent a group as defined in the description,

Benzo[3,4]cyclobuta[1,2-c]pyrrole compounds

A compound selected from those of formula (I): ##STR1## wherein: R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be identical or different, represent hydrogen, halogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, trihaloalkyl, or any pair may form a heterocycle,

Indan-1-ol compounds

A compound of formula (I): ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, X--Y, A, Z and Z' are as defined in the description, in the form of the cis or trans isomers each in racemic or optically active form, and acid addition salts thereof, and medicinal products containing the same are useful in the treatment of diseases of the central nervous system or of manifestations of pain.

Indanol compounds

New 2-aminoindan compounds of formula: ##STR1## wherein: n, Ar, R, E, X.sub.1, X.sub.2, X.sub.3, and X.sub.4 are as defined in the description, in the form of a racemic mixture and in the form of optical isomers, and physiologically-tolerable acid addition salts thereof. The products of the invention are useful as medicaments and exhibit selective binding affinity for the 5HT.sub.1B receptors.

2-aminoindan compounds as 5HT.sub.1B antagonists

New N-arylpiperidine compounds of formula: ##STR1## wherein: A, m, R, E, n and Ar are as defined in the description, the isomers thereof and the addition salts thereof with a pharmaceutically acceptable acid, and medicinal products containing the same are useful in the treatment of disorders involving the serotininergic system.

N-aryl piperidine compounds as 5HT.sub.1B antagonists

A compound of formula (I): ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, X-Y, A, Z and Z' are as defined in the description, in the form of the cis or trans isomers each in racemic or optically active form, and acid addition salts thereof, and medicinal products containing the same are useful in the treatment of diseases of the central nervous system or of manifestations of pain.

A compound selected from those of formula: ##STR1## wherein: A--B, n, D and E are as defined in the specification, their racemic mixtures, and their optical isomers, and also the physiologically tolerable salts thereof with appropriate acids. The products of the invention may be used therapeutically.

New compounds of formula: ##STR1## wherein: A--D--E, X, n and R are as defined in the description, in racemic form and in the form of optical isomers, and their addition salts with pharmaceutically acceptable acids. Those compounds may be used as medicaments.

Tetracyclic 1,4-oxazine compounds

Growing community of inventors

Viroflay, France

Bertrand Goument